
Read More
Pharma Giant Expands with Strategic Acquisition in Singapore...
The company has been actively expanding its product pipeline, with over 70 commercialized products a...

The company has been actively expanding its product pipeline, with over 70 commercialized products a...

The stock gave multibagger returns of over 200 per cent in just 1 year and a whopping 400 per cent i...

Of significant note is the remarkable reduction in the company's debt-to-EBITDA ratio, which has und...

The stock has surged nearly 107 per cent in the last year, transforming into a multibagger stock for...